Vigil Neuroscience, Inc.
VIGLDelisted Aug 5, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827087
Vigil Neuroscience, Inc. was delisted on Aug 5, 2025; its insiders filed their last Form 4 on Aug 7, 2025; 78 institutions reported holding it in 13F filings for Q2 2025, worth $265.8M in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Vigil Neuroscience, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- +4 vs. Q4 2022
- Shares held
- 25.1M
- +69.6K (+0.3%) vs. Q4 2022
- Total value
- $245.4M
- −$66.9M (−21.4%) vs. Q4 2022
- New holders
- 4
- 11 more added
- Sold out
- 0
- 10 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VIGL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 2 | $4.55K |
| Q2 2025 | 78 | $265.8M |
| Q1 2025 | 50 | $44.5M |
| Q4 2024 | 51 | $38.4M |
| Q3 2024 | 52 | $94.2M |
| Q2 2024 | 58 | $104.5M |
| Q1 2024 | 54 | $90.5M |
| Q4 2023 | 46 | $84.4M |
| Q3 2023 | 45 | $137.7M |
| Q2 2023 | 47 | $242.1M |
| Q1 2023 | 41 | $245.4M |
| Q4 2022 | 37 | $312.3M |
| Q3 2022 | 33 | $222.7M |
| Q2 2022 | 35 | $44.6M |
| Q1 2022 | 47 | $125.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Vigil Neuroscience, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 86 | $842 | 0.00% | +1+1.2% | Added |
| State of Wyoming | 101 | $989 | 0.00% | −3−2.9% | Reduced |
| UBS Group AG | 592 | $5.80K | 0.00% | +82+16.1% | Added |
| Tower Research Capital LLC (TRC) | 1,482 | $15.0K | 0.00% | −350−19.1% | Reduced |
| Cannell Capital LLC | 8,044 | $78.8K | 0.02% | 00.0% | Unchanged |
| Man Group plc | – | $114.5K | 0.00% | – | New |
| 683 Capital Management, LLC | 15,092 | $147.8K | 0.01% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 18,705 | $183.1K | 0.00% | +18,705 | New |
| Bank of America Corp | 19,322 | $189.2K | 0.00% | +9,426+95.3% | Added |
| Northern Trust Corp | 22,235 | $217.7K | 0.00% | +3,441+18.3% | Added |
| Goldman Sachs Group Inc | 24,826 | $243.0K | 0.00% | −48,185−66.0% | Reduced |
| Jane Street Group, LLC | 27,184 | $266.1K | 0.00% | +27,184 | New |
| State Street Corp | 35,739 | $349.9K | 0.00% | 00.0% | Unchanged |
| Bank of Montreal | 41,293 | $495.5K | 0.00% | −16,807−28.9% | Reduced |
| Morgan Stanley | 58,344 | $571.2K | 0.00% | +49,252+541.7% | Added |
| Susquehanna International Group, LLP | 58,718 | $574.8K | 0.00% | +31,343+114.5% | Added |
| Millennium Management LLC | 71,381 | $699.0K | 0.00% | +71,381 | New |
| FMR LLC | 86,724 | $849.0K | 0.00% | +74+0.1% | Added |
| Citigroup Inc | 91,398 | $894.8K | 0.00% | −2,529−2.7% | Reduced |
| BlackRock Inc. | 102,086 | $999.4K | 0.00% | −305−0.3% | Reduced |
| Barclays PLC | 104,248 | $1.02M | 0.00% | −1,645−1.6% | Reduced |
| Geode Capital Management, LLC | 112,392 | $1.10M | 0.00% | +8,625+8.3% | Added |
| Laurion Capital Management LP | 130,200 | $1.27M | 0.06% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 172,308 | $1.69M | 0.51% | +3,462+2.1% | Added |
| Logos Global Management LP | 188,390 | $1.84M | 0.26% | 00.0% | Unchanged |
| Trustees of Columbia University in the City of New York | 192,973 | $1.89M | 3.38% | 00.0% | Unchanged |
| Harvard Management Co Inc | 289,460 | $2.83M | 0.30% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 448,891 | $4.39M | 0.09% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 471,958 | $4.62M | 0.11% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 560,595 | $5.49M | 2.26% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 616,786 | $6.04M | 0.40% | 00.0% | Unchanged |
| Vanguard Group Inc | 728,613 | $7.13M | 0.00% | −8,400−1.1% | Reduced |
| BVF Inc | 1,813,633 | $17.8M | 0.65% | 00.0% | Unchanged |
| Deep Track Capital, LP | 2,025,137 | $19.8M | 0.84% | −79,037−3.8% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 2,052,010 | $20.1M | 0.45% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,161,796 | $21.2M | 0.02% | −2,120−0.1% | Reduced |
| Artal Group S.A. | 2,243,352 | $22.0M | 1.30% | 00.0% | Unchanged |
| Northpond Ventures, LLC | 4,214,498 | $41.3M | 23.58% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 5,836,874 | $57.1M | 7.74% | 00.0% | Unchanged |
| Coppell Advisory Solutions LLC | 3,298 | – | – | +2,998+999.3% | Added |
| Coppell Advisory Solutions Corp. | 3,298 | – | – | +2,998+999.3% | Added |